Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6652W HIGH $19.91
Volume
27.90 K
Value Traded
120.34 K
Short % Float
4.1%
-14.6%Week
-44.26%1 Month
+246.28%3 Month
-49.56%6 Month
-99.64%5 Year
-99.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.94 M
EPS (TTM)
-23.13
P/E Ratio
-
Ent. Value
-2.25 M
Total Shares
547.77 K
Float Shares
550.00 K
Insiders
0.06%
Institutions
2.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ARTL Catalyst Timeline
Dated clinical, regulatory and corporate events for Artelo Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Artelo Biosciences, Inc.
403Total events
10Upcoming
43Tier-1 (high impact)
2018 to 2038Coverage
Upcoming catalysts 2
Event history 50
▲Composition Patent FiledART27IP / Competition
Artelo files provisional patent application covering ART27.13 for obesity, alone and with GLP-1 receptor agonists
obesitysource ↗
▲Additional DataART27Clinical Data
New DIO-2 findings: appetite suppression, improved oral glucose tolerance, increased bone mineral density, lipid reductions
diet-induced obesitysource ↗
▲Preclinical PoCART27Preclinical
Additional DIO-2 nonclinical findings: combination with semaglutide improved oral glucose tolerance and increased bone mineral density
obesitysource ↗
▲Preclinical PoCART27Preclinical
Previously reported DIO-2 results: ART27.13 monotherapy ~20% weight loss, comparable to semaglutide
obesitysource ↗
▲Additional DataART27Clinical Data
Previously reported DIO-2 results: ~20% weight loss monotherapy, ~80% of weight lost as fat
diet-induced obesitysource ↗
●R&D DayPresentation
Artelo CEO to present at H.C. Wainwright 28th Annual Global Investment Conference
▲Patent GrantedART27IP / Competition
Japanese Patent Office issued notification of allowance for ART27.13 commercial formulation patent
▲Patent GrantedART27IP / Competition
USPTO issues Notice of Allowance for patent covering commercial formulation of ART27.13
▲Interim AnalysisART27Trial
Interim Phase 2 CAReS data showed improvement in body weight, lean body mass and physical activity
cancer anorexia cachexiasource ↗
▲First Patient DosedART27Trial
First patient dosed in DREAM study
glaucoma or ocular hypertensionsource ↗
▲PublicationPresentation
Publication of review article in British Journal of Clinical Pharmacology evaluating low-dose CBD
▲Oral PresentationART26Presentation
Nonclinical osteoarthritis study results presented at International Cannabinoid Research Society 2026 Annual Symposium
osteoarthritis painsource ↗
▲Preclinical PoCART27Preclinical
Positive results in nonclinical model of paclitaxel-induced peripheral neuropathy
paclitaxel-induced peripheral neuropathysource ↗
▲Oral PresentationART27Presentation
Interim CAReS results presented at ICRS 2026 Annual Symposium
cancer-related anorexia cachexia syndromesource ↗
▲Poster PresentationART26Presentation
Presentation of preclinical data for ART26.12 in spinal cord injury-induced neuropathic pain at ICRS 2026
neuropathic pain from spinal cord injurysource ↗
◆Enrollment UpdateART26Trial
Multiple ascending dose enrollment being prepared for Q3 2026
chemotherapy-induced peripheral neuropathysource ↗
▲Oral PresentationART27Presentation
Interim CAReS results presented at ICRS 2026 Annual Symposium
cancer-related anorexia cachexia syndromesource ↗
▲Interim AnalysisART27Trial
Interim analysis from CAReS Phase 2 study
cancer-related anorexia cachexia syndromesource ↗
◆Oral PresentationART26Presentation
Presentation of multi-omics analysis for ART26.12 at ICRS 2026
cancer, pain, dermatologic, neurological conditionssource ↗
▲Oral PresentationART26Presentation
Presentation of biomarker data for ART26.12 at ICRS 2026
chemotherapy-induced peripheral neuropathysource ↗
◆Oral PresentationART26Presentation
Oral presentation of ART26.12 human metabolite data at 7th RSC-BMCS/DMDG Conference
painsource ↗
▲Enrollment CompleteART26Trial
Single Ascending Dose (SAD) clinical study of ART26.12 completed
chemotherapy-induced peripheral neuropathy (CIPN)source ↗
▲Partnership / LicenseCorporate
Strategic collaboration with ScienceMachine to accelerate FABP5 inhibitor development
▲PublicationART26Presentation
Peer-reviewed publication on FABP5 inhibitor ART26.12 in European Journal of Pain
painsource ↗
▲Trial CompletionART26Trial
Completed Phase 1 SAD study with zero adverse events attributed to ART26.12
painsource ↗
◆First Patient DosedART27Trial
First patient enrollment anticipated in Q2 2026
glaucoma or ocular hypertensionsource ↗
◆Trial InitiationART27Trial
Third-party fully funded clinical study planned to start in Q2 2026 to evaluate ART27.13 in glaucoma patients
glaucomasource ↗
▲Quarterly UpdateCorporate
Regained compliance with Nasdaq Equity Rule and Annual Shareholders Meeting Rule
▼Equity OfferingCorporate
Private placement of 3,188,407 shares and warrants at $3.45 per unit for gross proceeds of $11.0 million
◆Preclinical PoCART27Preclinical
Initiation of non-clinical study to evaluate ART27.13 in models relevant to GLP-1-associated muscle preservation
muscle preservation associated with GLP-1 therapysource ↗
◆Composition Patent FiledART27IP / Competition
Filing of provisional patent application covering use of cannabinoid receptor agonism to prevent or mitigate muscle loss associated with GLP-1 therapy
muscle loss associated with GLP-1 therapysource ↗
◆PublicationART27Presentation
Publication of independent peer-reviewed research validating differentiated pharmacology of ART27.13 compared to other CB2 agonists
▲Trial InitiationART27Trial
Investigator-sponsored clinical study in glaucoma initiated
glaucomasource ↗
▲Trial InitiationART27Trial
Investigator-initiated study agreement signed for ART27.13 in glaucoma
glaucoma or ocular hypertensionsource ↗
▲Patent GrantedART12IP / Competition
US composition of matter patent for ART12.11 granted, enforceable until December 10, 2038
▲FDA Feedback ReceivedART12FDA Meeting
Constructive feedback from regulatory authorities received for ART12.11
▲PublicationSBFI103Presentation
Publication of peer-reviewed study on SBFI103 in Neurobiology of Disease
stress-induced anxiety and depressionsource ↗
▲Interim AnalysisART27Trial
Interim Phase 2 data showing restoration in body weight versus continued weight loss
cancer anorexia cachexia syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How ARTL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-12-31 | ART27.13 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ARTL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ART27.13 | cancer-related anorexia | Phase 2 | 2026-08-17 | more than 60% of participants; all patients taking the highest dose; +6% weight gain over 12 weeks; ~5% weight loss on placeboRead More | Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 StudiesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FAVORITO TAMARA ADirector | Buy | 0 | $0.00 | 05/01/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in ARTL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ARTL for Q2 2026. | ||||
ARTL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARTL ranks across every disease it competes in
Competitive Position is a premium feature
See how ARTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARTL News
ARTL▲ +2.6%today
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Artelo Biosciences has been selected to present at BIO-Europe 2026, showcasing its clinical advancements, particularly with the FABP5 inhibitor ART26.12. The presentation will highlight promising data from clinical studies, including safety and efficacy in treating neuropathic pain and osteoarthritis. This event marks a significant opportunity for Artelo to engage with potential partners and expand its business development efforts.
Read more →ARTL▲ +76.1%on this news
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Artelo Biosciences has filed a provisional patent for ART27.13, targeting obesity treatment both as a monotherapy and in combination with GLP-1 receptor agonists like semaglutide. Recent studies show ART27.13 led to significant weight loss and improved metabolic parameters in obese mice. The findings suggest a broader role for ART27.13 in weight and metabolic regulation, potentially enhancing existing therapies.
Read more →ARTL▼ -29.8%on this news
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Artelo Biosciences reported that its oral drug ART27.13 resulted in a 20% weight loss in obese mice, matching semaglutide's effects. When combined with semaglutide, the weight loss reached approximately 40%. The findings suggest ART27.13 may act as a metabolic regulator, specifically targeting obesity without affecting lean animals.
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Artelo Biosciences, a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Gregory D. Gorgas will present on September 11, 2026, and the company will hold one-on-one meetings with investors during the event. Artelo focuses on developing treatments for various conditions, including cancer and pain.
Read more →ARTL▼ -7%on this news
Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences has announced a 1-for-9 reverse stock split to improve the marketability and liquidity of its common stock. The split will take effect on August 31, 2026, with no fractional shares issued. Shareholders will retain their ownership percentage, and all outstanding warrants will adjust accordingly.
Read more →ARTLArtelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences announced a notice of allowance from the Japanese Patent Office for its patent application regarding ART27.13, a dual cannabinoid agonist. This patent aligns with protections already granted in the U.S. and Europe, extending the drug's market potential until 2041. ART27.13 is currently in Phase 2 trials for cancer-related anorexia and glaucoma, showing promising early results.
Read more →ARTL▼ -8.8%on this newsshared move
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Artelo Biosciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its investigational drug ART27.13, which is currently in two Phase 2 studies. This patent covers the intended commercial formulation of ART27.13, expected to extend protection until 2041. The drug shows promise in treating cancer-related anorexia and glaucoma, with positive interim results reported.
Read more →ARTLArtelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Artelo Biosciences provided a business update and reported its Q2 2026 financial results, highlighting advancements in its clinical programs. The company is preparing to initiate a Phase 1 study for ART26.12, which has shown favorable safety and efficacy data. Additionally, ART27.13 has demonstrated promising interim results in improving body weight and activity in cancer patients. Despite a net loss of $2.4 million, Artelo remains optimistic about its future prospects.
Read more →ARTLArtelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
Artelo Biosciences has announced the enrollment of the first patient in its Phase 2 clinical trial, the DREAM study, evaluating ART27.13 for glaucoma treatment. This study aims to assess the efficacy of ART27.13, a synthetic cannabinoid, in lowering intraocular pressure. Initial results are anticipated in Q4 2026, with funding provided by Glaucoma UK and the HSC R&D Division.
Read more →ARTLNew Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
A recent analysis published in the British Journal of Clinical Pharmacology reveals that widely sold non-prescription CBD products lack therapeutic efficacy due to inadequate dosing. Artelo's proprietary formulation, ART12.11, aims to enhance bioavailability and address these limitations. The study underscores the importance of evidence-based drug development in optimizing CBD treatments.
Read more →ARTLArtelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Artelo Biosciences announced promising results from a nonclinical study of ART26.12, a FABP5 inhibitor, showing significant pain relief in osteoarthritis comparable to naproxen, but with less gastric damage. The findings suggest ART26.12 could provide a safer alternative for chronic pain management. Clinical trials for ART26.12 are set to begin in Q4 2026.
Read more →ARTL▲ +10.5%on this newsshared move
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Artelo Biosciences has reminded shareholders to vote in advance of its Annual Meeting on July 17, 2026. The company emphasizes the importance of submitting proxies to establish quorum and efficiently conduct business. Shareholders are encouraged to review proxy materials and participate in the voting process.
Read more →ARTLArtelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences has announced positive results from nonclinical studies of ART27.13, a cannabinoid receptor agonist, in treating neuropathic pain associated with paclitaxel chemotherapy. The findings suggest that ART27.13 may have broader applications in cancer supportive care, particularly for patients suffering from anorexia cachexia syndrome. Interim results from the CAReS Phase 2 clinical study also indicate improvements in body weight and activity levels.
Read more →ARTLArtelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
Artelo Biosciences announced promising preclinical data for ART26.12, a selective FABP5 inhibitor, showing its potential to alleviate neuropathic pain associated with spinal cord injury. The findings, presented at a symposium in France, suggest ART26.12 could serve as a novel, non-opioid analgesic. The company emphasizes the need for effective treatments in chronic pain management.
Read more →ARTLArtelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Artelo Biosciences presented findings at the ICRS 2026 Annual Symposium, highlighting the potential of its FABP5 inhibitor, ART26.12, in modulating lipid-signaling pathways across various disease models. The research indicates a mechanistic link involving linoleic acid, suggesting broad therapeutic applications. The company emphasizes the drug's favorable safety profile and its potential in treating conditions like chemotherapy-induced peripheral neuropathy.
Read more →ARTLArtelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
Artelo Biosciences presented promising Phase 1 clinical data for ART26.12, a selective FABP5 inhibitor, at the ICRS 2026 Annual Symposium. The study showed a favorable safety profile and predictable pharmacokinetics in healthy volunteers. Additionally, new biomarker analyses indicated potential indicators of target engagement, supporting further clinical development of ART26.12.
Read more →ARTLArtelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo Biosciences presented promising data on its lead candidate ART26.12 at a conference, highlighting a low-risk metabolite profile from a recent clinical study. The findings suggest that the majority of drug-related exposure comes from the parent compound, indicating a favorable pharmacokinetic profile. This could streamline future development and reduce risks associated with drug metabolism.
Read more →ARTLArtelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
Artelo Biosciences has released a business update detailing its progress in clinical studies and financial results for the first quarter of 2026. The company noted significant advancements in its lead drug ART26.12, which is advancing to multiple ascending dose studies after promising Phase 1 results. ART27.13 also showed positive interim results for patients with cancer-related anorexia. Artelo has strengthened its financial position through a capital raise, allowing further development of its pipeline and fostering potential strategic partnerships.
Read more →ARTL▼ -5.3%on this news
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
Artelo Biosciences has announced a strategic collaboration with ScienceMachine to enhance the development of its FABP5 inhibitor platform. This partnership aims to leverage AI technology to analyze extensive biological datasets, potentially accelerating the identification of new mechanisms and therapeutic opportunities. The collaboration is expected to provide insights into ART26.12, Artelo's lead FABP5 inhibitor, and improve drug development strategies.
Read more →About Artelo Biosciences, Inc.
Headquarters505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next ARTL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime